bioihbjkbjnl/mcl2 huggingface dataset:
Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice
Condition: Pancreatic Cancer
MeSH terms: Pancreatic Neoplasms
Study type: Observational

Summary: 
      Currently, X-rays and blood tests often miss pancreatic cancer. In this study, we are
      collecting and studying the fluid produced by the pancreas as a way to detect pancreatic
      cancer at an earlier stage.
    

Detailed description: 
      Pancreatic cancer is very difficult to detect and treat, and patients with this cancer
      generally live fewer years than patients with other types of cancer. Part of the reason why
      pancreatic cancer is so hard to treat is because it is usually discovered when it is too
      advanced to be able to treat. The goal of this protocol is to find a way to detect pancreatic
      cancer earlier, when it is still treatable in order to improve the survival of patients.

      The pancreas is a gland which produces digestive juices that mix with food in the intestines.
      Normal patients as well as patients with pancreatic cancer produce these juices. Other
      researchers have collected this fluid from very small numbers of patients and their results
      suggest that pancreatic fluid can be used to detect pancreatic cancer. One of the major
      issues with these results is that pancreatic fluid from only a very few number of patients
      has been collected and analyzed. In order to find out whether the pancreatic fluid can be
      used as a standard test for pancreatic cancer, the fluid from a greater number of patients
      needs to be analyzed. Also, of all the different chemicals in the pancreatic fluid, in this
      study we will try to figure out what the most important chemicals are in diagnosing
      pancreatic cancer.
    

Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Group A: Participants with a confirmed diagnosis of a pancreatic adenocarcinoma will be
        enrolled in this study. Potential participants will be identified from the Surgical
        Oncology and Gastroenterology outpatient settings.

        Group B: Participants with a confirmed diagnosis of chronic pancreatitis will be enrolled
        in this study. Participants will be derived from the Gastroenterology and Gastrointestinal
        Surgery outpatient setting.

        Group C: Participants undergoing endoscopy for non-pancreatic, non-neoplastic indications.
        The typical patient population we anticipate recruiting to this group with be those with
        non-malignant, non-pancreatitis biliary calculous disease. Participants will be derived
        from the Gastroenterology outpatient setting.
      
Biospecimen description: 
      samples will be in 3 differant cohorts;

        1. Subject with biopsy-proven Pancreatic Adenocarcinoma of the pancreas

        2. Subjects witha diagnosis of Pancreatitis

        3. Subject with NO pancreatic abnormality
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process
Condition: Diabetes; Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This trial is conducted in Europe. The aim of this trial is to compare insulin aspart
      produced by current process and the NN2000 process.
    


Intervention name(s): insulin aspart
Intervention type(s): Drug
Intervention description(s): Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
Intervention MeSH terms: Insulin Aspart
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Effects of Short-term Growth Hormone in HIV-infected Patients
Condition: HIV Lipodystrophy
MeSH terms: Lipodystrophy
Study type: Interventional

Summary: 
      The purpose of this study is to examine the short-term effects of two different doses of
      growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's
      secretion of growth hormone and the body's glucose metabolism. We hypothesize that growth
      hormone administration will alter the body's endogenous pulsatile growth hormone secretion
      and that higher dose growth hormone may decrease insulin sensitivity. We hypothesize that
      growth hormone releasing hormone will augment endogenous GH pulsatility and be neutral to
      insulin sensitivity.
    

Detailed description: 
      The primary objective of this study is to determine the differential effects of growth
      hormone releasing hormone (GHRH) vs. low dose physiologic growth hormone (GH) vs. higher dose
      GH treatment and withdrawal on endogenous overnight growth hormone secretion and pulsatility,
      as well as insulin-stimulated glucose uptake. Subjects with HIV-infection will be randomized
      to receive one of three treatments: GHRH 2mg/day, or growth hormone 6mcg/kg/day (physiologic
      "low" dose), or growth hormone 2mg/day ("higher" dose) for 2 weeks. At baseline and after two
      weeks of treatment, we will assess overnight growth hormone by frequent sampling as well as
      insulin stimulated glucose uptake by clamp. Subjects will then stop the treatment and will
      return for an identical assessment after a 2 week withdrawal period.
    

Intervention name(s): Growth hormone; Growth Hormone Releasing Hormone
Intervention type(s): Drug; Drug
Intervention description(s): Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks; Tesamorelin (GHRH) 2mg SC QD x 2 weeks
Other intervention name(s): rhGH from Teva Pharmaceuticals
Intervention MeSH terms: Hormones; Growth Hormone-Releasing Hormone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: HIV lipodystrophy; growth hormone; growth hormone releasing hormone
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to determine whether treatment with daily oral dose of AZD8529
      40 mg administered over 28 days is safe, well tolerated and improves main symptoms of
      schizophrenia in adult schizophrenia patients.
    


Intervention name(s): AZD 8529; Risperidone; Placebo to match AZD8529; Placebo to match risperidone
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): 40mg oral daily capsule administered as a single dose in the morning for 28 days; 4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days; Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period; Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
Other intervention name(s): Risperdal
Intervention MeSH terms: Risperidone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Schizophrenia; Hallucinations; Paranoia; Inpatient schizophrenia clinical trial
An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial
Condition: Gastric Cancer
MeSH terms: Stomach Neoplasms
Study type: Interventional
Phase: Phase 3

Summary: 
      Gastric cancer is a major health issue and one of the most common malignance in Korea. With
      the popularization of cancer screenings and increasing the average lifespan, the number of
      gastric cancer patients is increased. In the past, most of the research were concerned with
      survival and recovery after cancer surgery. However, as the medical technology had been
      developed and recovery rate and survival rate of cancer patients had risen, the patients
      wanted to return to a daily life and desire for participation for leisure. In other words,
      the patients who underwent surgery wants to maintain a high quality of life(QOL) level as
      like prior to cancer surgery.
    

Detailed description: 
      There are many reports on the effect of the exercise program after cancer surgery. In
      addition, exercise program was associated with improving the QOL and functional recovery,
      decreasing a mood of depression, maintaining a muscle mass and improving the survival rate.

      However, the subject patients of previous studies were Western people. Therefore, The results
      were not disclosed whether the exercise program suited to the body characteristics of Korean
      people. Furthermore there was no exercise program studies for the gastric cancer patients.

      Medical service for cancer patients care should include not only diagnosis, treatment as like
      surgery but efforts on enhancing the quality of life. In other words, post-management
      education and management program as like exercise program are necessary for the cancer
      patients after surgery. Thus, the investigators have done the pilot study about how to
      practice the exercise program and how to evaluate the effect on the recovery. Based on the
      result of pilot study which could identify the safety and the feasibility , the investigators
      would like to do a prospective randomized controlled study to prove the effect of exercise
      program after surgery
    

Intervention name(s): physical activity intervention
Intervention type(s): Behavioral
Intervention description(s): Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Supportive Care
Keywords: Gastric cancer; minimally invasive gastrectomy; Physical activity intervention
Comparative Effectiveness of School-based Caries Prevention
Condition: Dental Caries; Quality of Life
MeSH terms: Dental Caries
Study type: Interventional

Summary: 
      Dental caries (tooth decay) is the most prevalent childhood disease in the world. Multiple
      interventions are available to treat and prevent caries. The aim of the proposed study is to
      compare the benefit of silver diamine fluoride (SDF) and fluoride varnish versus fluoride
      varnish and glass ionomer sealants. This study is a five-year, cluster randomized, pragmatic
      controlled trial conducted in public elementary schools in New York City.
    

Detailed description: 
      Dental caries is the most prevalent childhood disease in the world and can lead to infection,
      pain, reduced quality of life, and negative educational outcomes. Multiple prevention agents
      are available to arrest and prevent dental caries, however little is known of the comparative
      effectiveness of combined treatments in pragmatic settings. The aim of the presented study is
      to compare the benefit of silver diamine fluoride and fluoride varnish versus fluoride
      varnish and glass ionomer therapeutic sealants in the arrest and prevention of dental caries.

      This is a longitudinal, pragmatic, cluster randomized, single-blind, non-inferiority trial to
      be conducted in low-income minority children enrolled in public elementary schools in New
      York City, New York, United States, from 2018-2023. The primary objective is to assess the
      non-inferiority of alternative agents in the arrest and prevention of dental caries.
      Secondary objectives are to assess oral health-related quality of life and educational
      outcomes. Caries arrest will be evaluated after two years, and caries prevention and
      secondary outcomes will be assessed at the completion of the study. Data analysis will follow
      intent to treat, and statistical analyses will be conducted using a two-sided significance
      level of 0.05.

      Notably, the standard of care for dental caries is office-based surgery, which presents
      multiple barriers to care including cost, fear, and geographic isolation. The simplicity and
      affordability of silver diamine fluoride may be a viable alternative for the arrest and
      prevention of dental caries in high-risk children.
    

Intervention name(s): Silver Diamine Fluoride; Fluoride Varnishes; Glass Ionomer
Intervention type(s): Device; Device; Device
Intervention description(s): Silver diamine fluoride (SDF); Fluoride varnish (FV); Glass Ionomer Sealants (GC Fuji IX)
Other intervention name(s): Advantage Arrest
Intervention MeSH terms: Fluorides; Fluorides, Topical
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Two-arm, parallel, non-inferiority cluster randomized trial
Masking: Single (Outcomes Assessor)
Primary purpose: Prevention
Keywords: dental caries; caries arrest; caries prevention; quality of life; silver diamine fluoride; sealants; interim therapeutic restorations; student achievement; school attendance
Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia
Condition: Emergence Delirium; Extubation Time; Heart Rate; Postoperative Analgesia; Blood Pressure
MeSH terms: Delirium; Emergence Delirium
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      Dexmedetomidine (DEX) is safe and effective in reducing ED following sevoflurane anesthesia.
      The investigators intend to study the efficacy of DEX in reducing ED in children undergoing
      tonsillectomy with and without adenoidectomy using total intravenous anesthesia (TIVA) with
      propofol .
    


Intervention name(s): Dexmedetomidine; Normal saline; Bispectral index; Train of four ratio
Intervention type(s): Drug; Drug; Device; Device
Intervention description(s): Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.; Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.; Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60; Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
Other intervention name(s): alpha-2 agonist; placebo; BIS; TOF-Watch
Intervention MeSH terms: Dexmedetomidine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary purpose: Prevention
Keywords: dexmedetomidine; emergence delirium; anesthesia; propofol; children
Role of Pioglitazone in Preventing Diabetes
Condition: Diabetes
Study type: Interventional
Phase: Phase 1

Summary: 
      A three year prospective, double blinded, placebo controlled, randomized clinical trial in
      impaired glucose tolerance (IGT) subjects to study the effect of pioglitazone in preventing
      the conversion to Diabetes.
    

Detailed description: 
      A randomized controlled study was designed to find out whether pioglitazone will prevent the
      conversion to diabetes in subjects who are non obese and with impaired glucose tolerance.

      It is a double blind prospective study for 3 years. The study was started in October 2003 and
      randomization was completed in May 2005. A total of 6643 subjects were screened and 406 were
      randomized either to pioglitazone or placebo(investigator blinded-groups assigned A and B).
      At randomisation subjects were given standard advice on diet,exercise and benefits of life
      style modifications.

      Subjects both male and female, aged between 35 and 55 years, with no known history of
      diabetes, willing and available for a 3 year study alone were screened. Pregnant women,
      subjects with major illness such as cancer, hepatic or cardiac diseases and on transferable
      jobs were excluded from the study. The initial dose of tablet was 15mg o.d. which was
      titrated after a month to 30 mg o.d. in subjects who did not show any adverse events.

      The subjects will be undergoing annual reviews with a repeat OGTT, for 3 years. An interim
      review at every six months is also being done. Proforma containing details of anthropometry,
      occupation, physical activity, dietary habits, details of medications, regularity of
      treatment will be done at each interview.

      The main expected outcomes of the study will be a reduction in conversion of IGT to diabetes
      and benefits of the drug on anthropometric variables and biochemical parameters.
    

Intervention name(s): Pioglitazone
Intervention type(s): Drug
Intervention MeSH terms: Pioglitazone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Prevention
Keywords: Impaired glucose tolerance; Intervention; Prevention
Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
Condition: Hypotrichosis
MeSH terms: Hypotrichosis
Study type: Interventional
Phase: Phase 4

Summary: 
      The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost
      .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is
      a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the
      Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will
      be day 270 period.
    


Intervention name(s): topical bimatoprost
Intervention type(s): Drug
Intervention description(s): topical bimatoprost will be applied one drop to each eyebrow each night.
Other intervention name(s): bimatoprost, Latisse, eyebrows
Intervention MeSH terms: Bimatoprost
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: mild; moderate
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Condition: Brain and Central Nervous System Tumors; Neuroblastoma
MeSH terms: Neuroblastoma; Nervous System Neoplasms; Central Nervous System Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Chemotherapy combined with radiation therapy may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by radiation
      therapy in treating children who have newly diagnosed malignant central nervous system
      tumors.
    

Detailed description: 
      OBJECTIVES:

        -  Determine the response rate to treatment with temozolomide in children with newly
           diagnosed malignant central nervous system tumors.

        -  Determine the toxicity of this treatment in these patients.

        -  Determine the overall survival in these patients for 18 months following the study after
           receiving this treatment.

      OUTLINE: Patients are stratified according to type of disease (ependymoma vs brain stem
      glioma vs malignant glioma vs other).

      Patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for a maximum
      of 4 courses in the absence of disease progression or unacceptable toxicity. Patients with a
      partial or complete response may receive an additional 8 courses of temozolomide following
      radiotherapy.

      PROJECTED ACCRUAL: A maximum of 100 patients (25 per stratum) will be accrued for this study
      over 24-36 months.
    

Intervention name(s): temozolomide
Intervention type(s): Drug
Intervention MeSH terms: Temozolomide
Primary purpose: Treatment
Keywords: childhood infratentorial ependymoma; childhood low-grade cerebral astrocytoma; childhood supratentorial ependymoma; childhood craniopharyngioma; localized resectable neuroblastoma; regional neuroblastoma; disseminated neuroblastoma; stage 4S neuroblastoma; childhood high-grade cerebral astrocytoma; childhood oligodendroglioma; childhood choroid plexus tumor; childhood grade I meningioma; childhood grade II meningioma; childhood grade III meningioma; untreated childhood supratentorial primitive neuroectodermal tumor; untreated childhood cerebellar astrocytoma; untreated childhood medulloblastoma; untreated childhood visual pathway and hypothalamic glioma; newly diagnosed childhood ependymoma; childhood central nervous system choriocarcinoma; childhood central nervous system embryonal tumor; childhood central nervous system mixed germ cell tumor; childhood central nervous system teratoma; childhood central nervous system yolk sac tumor
Lipid Peroxidation in Workers Exposed to Al,Ga,In,As,and Sb in Optoelectronic Industry
Condition: Urine
Study type: Observational

Summary: 
      To investigate whether exposure to Al, Ga, In, As, and Sb induces lipid peroxidation in
      humans. Whole blood and urine levels of 170 workers were analysed by use of ICP-MS. MDA, the
      product of lipid peroxidation was determined by HPLC
    

Detailed description: 
      If MDA as an index of lipid peroxidation can be induced by these metals. We will suggest
      reducing exposure to these metals
    

Time perspective: Other
Keywords: malondialdehyde optoelectronic vitamin complex